Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• SET-binding protein 1 (SETBP1) mutations are linked to poor prognoses in myeloid leukemias, particularly in relapsed juvenile myelomonocytic leukemia.
• The precise role of SETBP1 in the pathogenesis of Ras-driven leukemias remains incompletely understood.

Discussion:

• Co-expression of SETBP1 with Ras pathway mutations promotes oncogenic transformation and aggressive myeloid leukemia development in preclinical models.
• SETBP1 enhances the NRAS gene expression signature, leading to increased mitogen-activated protein kinase (MAPK) signaling and suppressed differentiation pathways.
• SETBP1 amplifies NRAS-driven MAPK phosphorylation, suggesting a critical role in pathway activation.

Key Insights:

• SETBP1-mutant myeloid leukemia cells remain sensitive to MAPK pathway inhibitors, including MEK inhibitors.
• Preclinical studies demonstrate that trametinib confers a survival advantage in a mouse model of NRAS/SETBP1-mutant disease.
• These findings highlight the therapeutic potential of targeting the MAPK pathway in SETBP1-mutant leukemias.

Outlook:

• SETBP1-mutant leukemia cells' susceptibility to trametinib offers encouraging preclinical data for clinical application.
• Further investigation into SETBP1's precise molecular mechanisms in leukemia is warranted.
• This research paves the way for novel therapeutic strategies targeting SETBP1-driven myeloid malignancies.